Study of Eribulin in Children With Cancer to Determine Safety
Status:
Terminated
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
This is a study for children with cancer with no curative treatment options. The
investigators will be giving eribulin, a new chemotherapy agent, for the first time to
children. This study is designed to determine a safe dose the investigators can give to
children in larger studies. The investigators will be monitoring the children on this study
for the safety of the treatment and levels of eribulin in the blood after treatment. The
investigators will also study the effect of the agent on the cancer.